These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30838895)

  • 1. Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion.
    Mendell JR; Chicoine LG; Al-Zaidy SA; Sahenk Z; Lehman K; Lowes L; Miller N; Alfano L; Galliers B; Lewis S; Murrey D; Peterson E; Griffin DA; Church K; Cheatham S; Cheatham J; Hogan MJ; Rodino-Klapac LR
    Hum Gene Ther; 2019 Jul; 30(7):794-801. PubMed ID: 30838895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.
    Griffin DA; Pozsgai ER; Heller KN; Potter RA; Peterson EL; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):390-404. PubMed ID: 33349138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.
    Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR
    Ann Neurol; 2010 Nov; 68(5):629-38. PubMed ID: 21031578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
    Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
    Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.
    Mendell JR; Rodino-Klapac LR; Rosales-Quintero X; Kota J; Coley BD; Galloway G; Craenen JM; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Viollet L; Walker CM; Sahenk Z; Clark KR
    Ann Neurol; 2009 Sep; 66(3):290-7. PubMed ID: 19798725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice.
    Pozsgai ER; Griffin DA; Heller KN; Mendell JR; Rodino-Klapac LR
    Gene Ther; 2016 Jan; 23(1):57-66. PubMed ID: 26214262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
    Herson S; Hentati F; Rigolet A; Behin A; Romero NB; Leturcq F; Laforêt P; Maisonobe T; Amouri R; Haddad H; Audit M; Montus M; Masurier C; Gjata B; Georger C; Cheraï M; Carlier P; Hogrel JY; Herson A; Allenbach Y; Lemoine FM; Klatzmann D; Sweeney HL; Mulligan RC; Eymard B; Caizergues D; Voït T; Benveniste O
    Brain; 2012 Feb; 135(Pt 2):483-92. PubMed ID: 22240777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very late-onset limb-girdle muscular dystrophy type 2D: A milder form with a normal muscle biopsy.
    Oliveira Santos M; Coelho P; Roque R; Conceição I
    J Clin Neurosci; 2020 Feb; 72():471-473. PubMed ID: 31836381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.
    Pozsgai ER; Griffin DA; Heller KN; Mendell JR; Rodino-Klapac LR
    Mol Ther; 2017 Apr; 25(4):855-869. PubMed ID: 28284983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results.
    Mendell JR; Pozsgai ER; Lewis S; Griffin DA; Lowes LP; Alfano LN; Lehman KJ; Church K; Reash NF; Iammarino MA; Sabo B; Potter R; Neuhaus S; Li X; Stevenson H; Rodino-Klapac LR
    Nat Med; 2024 Jan; 30(1):199-206. PubMed ID: 38177855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients.
    Xie Z; Hou Y; Yu M; Liu Y; Fan Y; Zhang W; Wang Z; Xiong H; Yuan Y
    Orphanet J Rare Dis; 2019 Feb; 14(1):43. PubMed ID: 30764848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel SGCA missense mutation in a case of limb-girdle muscular dystrophy 2D with the absence of four sarcoglycan proteins.
    Lu Y; Song X; Ji G; Wu H; Li D; Sun S
    Neuropathology; 2019 Jun; 39(3):207-211. PubMed ID: 30989758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoglycan A mutation in miniature dachshund dogs causes limb-girdle muscular dystrophy 2D.
    Mickelson JR; Minor KM; Guo LT; Friedenberg SG; Cullen JN; Ciavarella A; Hambrook LE; Brenner KM; Helmond SE; Marks SL; Shelton GD
    Skelet Muscle; 2021 Jan; 11(1):2. PubMed ID: 33407862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice.
    Nishiyama A; Ampong BN; Ohshima S; Shin JH; Nakai H; Imamura M; Miyagoe-Suzuki Y; Okada T; Takeda S
    Hum Gene Ther; 2008 Jul; 19(7):719-30. PubMed ID: 18578595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the Genetic Cause in Dutch Limb Girdle Muscular Dystrophy Families: A 27-Year's Journey.
    Ten Dam L; de Visser M; Ginjaar IB; van Duyvenvoorde HA; van Koningsbruggen S; van der Kooi AJ
    J Neuromuscul Dis; 2021; 8(2):261-272. PubMed ID: 33386810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and genetic spectrum of a large cohort of patients with δ-sarcoglycan muscular dystrophy.
    Alonso-Pérez J; González-Quereda L; Bruno C; Panicucci C; Alavi A; Nafissi S; Nilipour Y; Zanoteli E; Isihi LMA; Melegh B; Hadzsiev K; Muelas N; Vílchez JJ; Dourado ME; Kadem N; Kutluk G; Umair M; Younus M; Pegorano E; Bello L; Crawford TO; Suárez-Calvet X; Töpf A; Guglieri M; Marini-Bettolo C; Gallano P; Straub V; Díaz-Manera J
    Brain; 2022 Apr; 145(2):596-606. PubMed ID: 34515763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first case of primary alpha-sarcoglycanopathy identified in Albania, in two siblings with homozygous alpha-sarcoglycan mutation.
    Babameto-Laku A; Tabaku M; Tashko V; Cikuli M; Mokini V
    Genet Couns; 2011; 22(4):377-83. PubMed ID: 22303798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probable high prevalence of limb-girdle muscular dystrophy type 2D in Taiwan.
    Liang WC; Chou PC; Hung CC; Su YN; Kan TM; Chen WZ; Hayashi YK; Nishino I; Jong YJ
    J Neurol Sci; 2016 Mar; 362():304-8. PubMed ID: 26944168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmet needs and evolving treatment for limb girdle muscular dystrophies.
    Pozsgai E; Griffin D; Potter R; Sahenk Z; Lehman K; Rodino-Klapac LR; Mendell JR
    Neurodegener Dis Manag; 2021 Oct; 11(5):411-429. PubMed ID: 34472379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F.
    Pasteuning-Vuhman S; Putker K; Tanganyika-de Winter CL; Boertje-van der Meulen JW; van Vliet L; Overzier M; Plomp JJ; Aartsma-Rus A; van Putten M
    PLoS One; 2017; 12(8):e0182704. PubMed ID: 28797108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.